Infectious Diseases

< Back

Overview

The groups of this area aim to improve the outcomes of patients with infectious diseases. The Epidemiology and Public Health group focuses on the epidemiology and prevention of healthcare acquired infections, transmissible infections and on the new vaccines. The Infectious Diseases group focuses on improving the strategies of clinical problems observed in clinical practice. The Microbiology group studies the mechanisms of antimicrobial resistance, pathogenicity, genomic epidemiology and infectious diseases diagnostics. The CRIPS group focuses on developing translational and clinical research in critical care, while the SODIR group works in the areas of sepsis, organ dysfunction and resuscitation. There is also a group focused on clinical research on children’s infectious diseases and primary immunodeficiencies. Finally, the CIBBIM-Nanomedicine group Works in the synthesis, characterization and applications of engineered inorganic nanoparticles in the field of infectious diseases.

Publications

260
total
1322
impact factor
5.08
average impact factor

Group Leader: Tomàs Pumarola

The Research Group of Microbiology focuses on the study of the microbiology aspects involved in the infectious diseases aimed at improving developing basic, translational and clinical research that could improve the outcomes of patients with infectious diseases. We work with special interest in studying the mechanisms involved in antimicrobial resistance, molecular epidemiology, the microbiological aspects of bacterial, viral, parasitic and fungal infections as well as in the microbial mechanisms involved on their pathogenicity.

During 2019, the Research Group of Microbiology has developed projects aiming to elucidate the antimicrobial susceptibility, the mechanisms of antimicrobial resistance and population dynamics of clinically relevant pathogens such as Mycobacterium tuberculosis, Enterobacterales, Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, Staphylococcus aureus, respiratory viruses and Trypanosoma cruzi among others. We have characterized a case of respiratory toxigenic diphtheria following a 30-year diphtheria-free interval in Catalonia, we have identified new mechanisms of dissemination of antimicrobial resistance among bacterial population of cystic fibrosis patients, and we have identified new antimicrobial targets and new antimicrobial molecules that may be useful to fight against multidrug resistant bacteria. We ha stablished a viral respiratory infections surveillance programme among all the hospitals included in the Catalan Institute of Health. Finally, we have worked in the development and validation of new rapid diagnosis devices in the field of sepsis and respiratory tract infections.

VHIR Annual Report 2019